SGLT2 Inhibitor Prescription Rates Lag Behind in HFrEF, with Stephen Greene, MD
June 13th 2023Stephen Greene, MD, discusses the results of a recent GWTG-HF registry analysis, which concluded just 1 in 5 hospitalized patients with HFrEF were discharged with an SGLT2 inhibitor prescription and less than 10% were receiving all 4 classes of guideline-directed medical therapy.
Disease Activity-Guided Dosing Safe, Effective for up to 10 Years in Rheumatoid Arthritis
June 6th 2023Noortje van Herwaarden, MD, PhD, discusses the results of a 10-year follow-up from the DRESS study and how it informs use of disease activity-guided dose optimization in treatment of rheumatoid arthritis.
SGLT2 Inhibitors Could Lower Risk of Recurrent Gout Flares in People with Diabetes
June 4th 2023A new-user, active comparator cohort study from EULAR 2023 suggests use of SGLT2 inhibitors could lower risk of recurrent gout flares in people with type 2 diabetes and gout compared to use of DPP-4 inhibitors.
Pegloticase Use Could Contribute to Bone Remodeling in Gout Patients
June 2nd 2023An analysis of DECT imaging from the MIRROR trial is providing clinicians with insight into the potential for urate crystal resolution and bone remodeling with pegloticase plus methotrexate in patients with uncontrolled gout.
For People with Diabetes, Starting an SGLT2 Inhibitor Could Lower Gout Risk
June 2nd 2023An analysis of more than 20,000 people with type 2 diabetes suggests initiating therapy with an SGLT2 inhibitor, as a second-line treatment to metformin, was associated with a lower risk of developing gout relative to other second-line therapies.
Pegloticase Use and Quality of Life in Uncontrolled Gout, with Brian LaMoreaux, MD
June 1st 2023Brian LaMoreaux, MD, discusses data from an analysis of the MIRROR trial examining the impact of pegloticase plus methotrexate on patient-reported outcomes and quality of life measures among patients with uncontrolled gout.